Total Rx up 183 (15%). 1,406 vs 1,223 last week. New Rx are up 127 (11%), 1,258 vs 1,131 last week. Unique writer count is up 69 (10%), 782 vs 713 last week. LOvaza total RX are down 3,886 (-4%), 94,074 vs. 97,960 last week. New Rx are down 1,299 (-4%), 34,052 vs 35,351. Unique writer count is down 1,264 (-3%), 43,266 vs 44,530 last week.
This is a new drug it will take about 8 months to really show impact.I also think a 52 week low here is crazy with a fda approved drug it was a lot higher stock price before any drug...kinda rigged....i see a complete reversal after big monies milk it to a certain point.
usagary, not really unusual to be at 52 week low with approved drug. See PATH, whose Zecurity was approved. In the $3s and stock was as high as $7 I believe pre approval. WHy? As of now ,PATH is going it alone, looking for a buyer of the company or a big partner. Sound familiar?
Vascepa script numbers appear very weak but the most troubling thing I see with the script numbers are the Lovaza scripts. Typically the overall market expands with the addition of a new product and the addition of more sales reps selling and promoting a class of drugs in a particular market. Lovaza total scripts (-4%) as well as new scripts (-4%) appears to show the overall Omega3 market is actually shrinking rather than growing. This is not good at all. There is a net negative script count in the omega3 script numbers as a whole.